Introduction
============

Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a lifetime prevalence of one fourth of patients \>40 years old.^[@b1]^ With an aging population and increasing prevalence of known risk factors,^[@b2]^ the predominance of AF is increasing in the Western world.^[@b3]--[@b4]^ In addition to impairing quality of life,^[@b5]--[@b6]^ AF also increases the risk of stroke and thromboembolism,^[@b7]^ potentially leading to permanent disability and death.^[@b8]^ As a result, the appropriate management of this disease, including stroke prevention, is critically important. Previous studies in heart failure^[@b9]--[@b14]^ and myocardial infarction (MI)^[@b15]--[@b16]^ have shown that processes of care and outcomes improve when patients are cared for by a specialist versus a nonspecialist. Nevertheless, no AF data currently exist regarding differences in patient characteristics, treatment strategies, and treatment patterns across care settings.

We used the Outcomes Registry for Better Quality of Care in the Treatment of AF (ORBIT‐AF) database to compare patient characteristics and treatment strategies according to provider specialty (electrophysiology \[EP\] versus cardiology versus primary care/internal medicine).

Methods
=======

Data Sources and Study Population
---------------------------------

The ORBIT‐AF Registry is a multicenter, prospective, outpatient database of incident and prevalent AF. The registry is a nationwide collaboration of health care providers, including internists, primary care physicians, cardiologists, and EPs across the United States. Site investigators enrolled consecutive patients with AF who were ≥18 years of age, had electrocardiographic evidence of AF, were able to provide informed consent, and were able to adhere to follow‐up criteria. Patients were excluded who had a life expectancy of \<6 months or were diagnosed with AF secondary to an easily reversible condition. The primary source of data was a patient\'s medical record, which was entered into a Web‐based case report form. The rationale and design of ORBIT‐AF have been published previously.^[@b17]^ For this analysis, we included all patients in ORBIT‐AF with available baseline data who were enrolled from June 29, 2010, to August 9, 2011. A total of 174 sites contributed to the ORBIT‐AF baseline data. The current analysis was approved by the Duke University Institutional Review Board.

Definition of Provider Type
---------------------------

Provider specialty was the variable of interest for this analysis and was based on the specialty of the provider who resided at the specific enrollment site (EP, cardiology, internal medicine/primary care, or neurology). In addition, provider specialty was also captured for all types of providers who followed the care of the patient, including ascertainment of multiple providers (EP, cardiology, internal medicine/primary care, and neurology).

Atrial Fibrillation and Treatment Strategies
--------------------------------------------

The type of AF was classified according to treatment guidelines as first detected, paroxysmal, persistent, or permanent (long‐standing persistent).^[@b18]--[@b20]^ The following treatment strategies were compared across provider specialty: rhythm versus rate control, prior use of cardioversion, antiarrhythmic drugs, warfarin, and surgical interventions (AF radiofrequency ablation or surgical Maze procedure). Pharmacotherapy was also compared according to provider specialty, drug class, and individual antiarrhythmic and antithrombotic agents. Contraindications for oral anticoagulant therapy included both absolute and relative contraindications and were captured via checkboxes on the ORBIT‐AF data form.

Statistical Analysis
--------------------

Baseline characteristics were compared using the Kruskal--Wallis test for continuous variables and the χ^2^ test for categorical variables. We calculated the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism (CHADS~2~); the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age 65 to 74 years, sex category (CHA~2~DS~2~‐VASc); and the anticoagulation and risk factors in atrial fibrillation (ATRIA) prediction scores (as previously described)^[@b18]--[@b19],[@b21]^ to assess the predicted risk of downstream stroke and subsequent bleeding. The CHADS~2~ and CHA~2~DS~2~‐VASc scores were calculated and presented for each group to compare the baseline risk of thromboembolic events influencing treatment strategy.^[@b19]^ To illustrate the use of oral anticoagulation by provider type, we report the proportion of patients treated with oral anticoagulation (warfarin or dabigatran) according to CHA~2~DS~2~‐VASc scores and by provider type. We have only included patients without contraindications for treatment.

We assessed the effect of provider specialty (using cardiology as the reference group) on utilization of select treatment strategies using hierarchical multivariable logistic regression, with the following care processes as outcomes: rhythm control (versus rate), prior cardioversion, dabigatran (versus warfarin), oral anticoagulant, antiplatelet therapy, and anticoagulant clinic use to monitor international normalized ratio (INR) values. The hierarchical logistic regression model included patient‐level adjustment variables and a random intercept to account for provider variability.

The variables included for adjustment are age, female, race/ethnicity, payer/insurance, alcohol abuse, cognitive impairment/dementia, chronic obstructive pulmonary disease (COPD), dialysis, diabetes, heart failure, hypertension, significant valvular disease, obstructive sleep apnea, osteoporosis, peripheral vascular disease, prior stroke or transient ischemic attack (TIA), prior MI, gastrointestinal bleed, sinus node dysfunction, smoking status, thyroid disease, type of AF, heart rate, systolic blood pressure (BP), diastolic BP, interventricular conduction, left atrial diameter, left ventricular ejection fraction (LVEF) dysfunction, creatinine clearance (estimated using the Cockcroft--Gault formula), hematocrit, prior warfarin therapy, contraindication to anticoagulation, or currently on warfarin, dabigatran, or antiplatelet therapy (aspirin, clopidogrel, prasugrel, or ticagrelor). This list was modified according to the treatment strategies examined. All continuous variables were examined for linearity, and the specific treatment strategy and nonlinear variables were fit with linear splines where appropriate.

Missing data (all the adjustment variables \<2% except for creatinine clearance \[8%\], hematocrit \[11%\], % LVEF dysfunction \[14%\], and left atrial diameter \[27%\]) were multiply imputed. Final estimates and standard errors reflect the combined analysis over 5 imputed data sets. Adjusted associations of provider specialty with the care processes are displayed as odds ratios (ORs) with 95% confidence intervals (95% CIs). *P*\<0.05 was considered statistically significant. All analyses were performed using SAS software (versions 9.2 and 9.3; SAS Institute, Cary, NC).

Results
=======

A total of 10 097 outpatient AF patients were included in this study; baseline patient characteristics stratified according to provider specialty are shown in [Table 1](#tbl01){ref-type="table"}. Electrophysiologists were the primary AF care providers for 15.3% of patients, general cardiologists for 65.2%, and internal medicine/primary care physicians for 19.5%. Overall, 42.7% of patients saw 1 provider exclusively, 47.7% saw 2, and 9.2% saw \>2 specialty providers. Among those seen primarily by an internal medicine/primary care provider, 47.4% also received care from another provider (ie, EP or cardiologist). The proportion of patients seeing more than 1 provider was higher among patients seen primarily by a cardiologist (60.0% of these patients received care from other providers) or an electrophysiologist (57.2% of these patients received care from other providers).

###### 

Baseline Characteristics According to Provider Specialty

  Variable                                                               Overall (n=10 097)   Internal Medicine/Primary Care (n=1969)   Cardiology (n=6584)   Electrophysiology (n=1544)   *P* Value
  ---------------------------------------------------------------------- -------------------- ----------------------------------------- --------------------- ---------------------------- -----------
  Age, median (Q1, Q3)                                                   75 (67, 82)          76 (68, 82)                               75 (67, 82)           73 (64, 80)                  \<0.0001
  Female (%)                                                             4274 (42.3)          879 (44.6)                                2778 (42.2)           617 (40.0)                   0.0192
  Race/ethnicity, n (%)                                                  \<0.0001                                                                                                          
  Black                                                                  505 (5.0)            119 (6.0)                                 349 (5.3)             37 (2.4)                     
  Hispanic                                                               421 (4.2)            65 (3.3)                                  349 (5.3)             7 (0.5)                      
  White                                                                  9008 (89.2)          1755 (89.1)                               5763 (87.5)           1490 (96.5)                  
  Other[\*](#tf1-1){ref-type="table-fn"}                                 144 (1.4)            24 (1.2)                                  110 (1.7)             10 (0.7)                     
  Payer/insurance, n (%)                                                 \<0.0001                                                                                                          
  Medicaid                                                               468 (4.6)            118 (6.0)                                 314 (4.8)             36 (2.3)                     
  Medicare                                                               6562 (65.0)          1282 (65.1)                               4286 (65.1)           994 (64.4)                   
  Private                                                                2580 (25.6)          470 (23.9)                                1666 (25.3)           444 (28.8)                   
  Military                                                               109 (1.1)            11 (0.6)                                  72 (1.1)              26 (1.7)                     
  Other[\*](#tf1-2){ref-type="table-fn"}                                 284 (2.8)            64 (3.3)                                  185 (2.8)             35 (2.3)                     
  None                                                                   91 (0.9)             24 (1.2)                                  59 (0.9)              8 (0.5)                      
  CHADS~2~ score, mean (SD)                                              2.3 (1.3)            2.4 (1.3)                                 2.3 (1.3)             2.1 (1.3)                    \<0.0001
  CHA~2~DS~2~‐VASc score, mean (SD)                                      3.9 (1.8)            4.0 (1.8)                                 3.9 (1.8)             3.6 (1.8)                    \<0.0001
  ATRIA score, mean (SD)                                                 2.8 (2.0)            2.9 (2.0)                                 2.9 (2.0)             2.3 (1.9)                    \<0.0001
  Cognitive impairment/dementia, n (%)                                   309 (3.1)            118 (6.0)                                 171 (2.6)             20 (1.3)                     \<0.0001
  COPD, n (%)                                                            1652 (16.4)          372 (18.9)                                1060 (16.1)           220 (14.3)                   0.0007
  Dialysis, n (%)                                                        127 (1.3)            21 (1.1)                                  91 (1.4)              15 (1.0)                     0.2981
  Diabetes, n (%)                                                        2970 (29.4)          617 (31.3)                                1947 (29.6)           406 (26.3)                   0.0045
  Heart failure, n (%)                                                   3277 (32.5)          571 (29.0)                                2181 (33.1)           525 (34.0)                   0.0010
  Hypertension, n (%)                                                    8378 (83.0)          1669 (84.8)                               5516 (83.8)           1193 (77.3)                  \<0.0001
  Significant valvular disease, n (%)[\*](#tf1-3){ref-type="table-fn"}   2570 (25.5)          439 (22.3)                                1676 (25.5)           455 (29.5)                   \<0.0001
  Peripheral vascular disease, n (%)                                     1345 (13.3)          282 (14.3)                                872 (13.2)            191 (12.4)                   0.2290
  Prior stroke or TIA, n (%)                                             1521 (15.1)          342 (17.4)                                974 (14.8)            205 (13.3)                   0.0020
  Prior MI, n (%)                                                        1597 (15.8)          281 (14.3)                                1092 (16.6)           224 (14.5)                   0.0147
  Sinus node dysfunction, n (%)                                          1767 (17.5)          229 (11.6)                                1263 (19.2)           275 (17.8)                   \<0.0001
  Current smoker (among smokers), n (%)                                  584 (12.0)           124 (13.3)                                370 (11.7)            90 (11.3)                    0.0251
  Type of AF, n (%)                                                      \<0.0001                                                                                                          
  First detected                                                         475 (5.0)            120 (6.1)                                 324 (4.9)             31 (2.0)                     
  Paroxysmal                                                             5093 (50.0)          1028 (52.2)                               3172 (48.2)           893 (57.8)                   
  Persistent                                                             1695 (16.8)          290 (14.7)                                1080 (16.4)           325 (21.1)                   
  Permanent                                                              2820 (27.9)          528 (26.8)                                1997 (30.3)           295 (19.1)                   
  Heart rate, median (Q1, Q3)                                            70 (63, 80)          71 (64, 78)                               70 (63, 80)           70 (61, 79)                  0.0027
  Systolic BP, median (Q1, Q3)                                           126 (116, 138)       125 (118, 136)                            126 (116, 138)        122 (112, 136)               \<0.0001
  Diastolic BP, median (Q1, Q3)                                          72 (66, 80)          72 (66, 80)                               72 (66, 80)           72 (66, 80)                  0.3139
  LBBB, n (%)                                                            397 (3.9)            92 (4.7)                                  243 (3.7)             62 (4.0)                     \<0.0001
  LVEF \<30%, n (%)                                                      423 (4.2)            49 (2.5)                                  276 (4.2)             98 (6.4)                     0.0001
  Creatinine clearance (mL/min per 1.73 m^2^), median (Q1, Q3)           70 (50, 97)          66 (49, 94)                               69 (50, 96)           76 (54, 104)                 \<0.0001

Q1, Q3 indicates quartiles 1, 3; CHADS~2~, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism; CHA~2~DS~2~‐VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age 65 to 74 years, sex category; ATRIA, anticoagulation and risk factors in atrial fibrillation; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; MI, myocardial infarction; AF, atrial fibrillation; BP, blood pressure; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction.

Other includes American Indian/Alaskan native, Asian, Native Hawaiian or Pacific Native, and other.

Other includes state‐specific plan (non‐Medicaid) and other insurance.

Any moderate to severe valvular insufficiency or stenosis.

The overall median age of the cohort was 75 years (67, 82 \[Q1, Q3\] years), and 42.3% were women. The median CHADS~2~ score was 2 (1, 3 \[Q1, Q3\]). Patients who were cared for by an EP were more often younger, male, white, and privately insured and had fewer comorbidities than patients cared for by cardiologists or internal medicine/primary care physicians. Systolic BP was lower and creatinine clearance was higher in the EP patient group compared with the other groups ([Table 1](#tbl01){ref-type="table"}).

[Figure 1](#fig01){ref-type="fig"} displays the unadjusted CHADS~2~ scores categorized by type of provider; when compared with the other groups, patients cared for by EP providers had the lowest CHADS~2~ scores, whereas patients cared for by internal medicine/primary care providers had the highest scores. This relationship was similar for the CHA~2~DS~2~‐VASc scores. When compared with those cared for by EP providers, a higher proportion of patients with permanent AF were cared for by internal medicine/primary care providers ([Figure 2](#fig02){ref-type="fig"}). Electrophysiology providers had significantly higher proportions of paroxysmal and persistent AF patients compared with the other groups (*P*\<0.001). In addition, the use of oral anticoagulants differed by provider, as shown in [Figure 3](#fig03){ref-type="fig"}. The overall use of warfarin or dabigatran was 73.6% for internal medicine/primary care providers, 76.7% for cardiology providers, and 76.8% for EP (*P*=0.02 for difference between groups). Electrophysiology providers also prescribed warfarin or dabigatran more often than the other providers for patients with a CHA~2~DS~2~‐VASc ≥2.

![CHADS~2~ risk scores according to provider specialty. This figure displays the distribution of CHADS~2~ risk score by provider specialty. CHADS~2~ indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism; EP, electrophysiology; TIA, transient ischemic attack.](jah3-2-e000110-g1){#fig01}

![Type of atrial fibrillation distribution according to provider specialty. The distribution of AF type by provider specialty (first detected, paroxysmal, persistent, or permanent) is shown. AF indicates atrial fibrillation; EP, electrophysiology.](jah3-2-e000110-g2){#fig02}

![Use of oral anticoagulation (warfarin or dabigatran) according to CHA~2~DS~2~‐VASc score and provider specialty. This figure displays the distribution of oral anticoagulation use by provider specialty. CHA~2~DS~2~‐VASc indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or TIA or thromboembolism, vascular disease, age 65 to 74 years, sex category; AF, atrial fibrillation; EP, electrophysiology; TIA, transient ischemic attack.](jah3-2-e000110-g3){#fig03}

Management of Atrial Fibrillation by Provider: Unadjusted Results
-----------------------------------------------------------------

[Table 2](#tbl02){ref-type="table"} shows how patients\' AF was managed according to provider. Electrophysiology providers employed rate control in 55% of patients (with the remainder of their patients on rhythm control), whereas cardiology and internal medicine/primary care providers employed a rate control strategy in 70% of patients. Rhythm control was used in 44% of AF patients treated by EP providers versus approximately 30% and 29% of those treated by a cardiologist and internal medicine/primary care physician, respectively. Similarly, 42% of the EP provider patients had previously received cardioversion versus 29% of cardiology provider patients and 26% of internal medicine/primary care provider patients. Overall, EP providers used more catheter ablations and surgical interventions (*P*\<0.0001).

###### 

Atrial Fibrillation Management According to Provider Specialty

  Variable                                 Overall (n=10 097), n (%)   Internal Medicine/Primary Care (n=1969), n (%)   Cardiology (n=6584), n (%)   Electrophysiology (n=1544), n (%)   *P* Value
  ---------------------------------------- --------------------------- ------------------------------------------------ ---------------------------- ----------------------------------- -----------
  Rate control                             6859 (67.9)                 1388 (70.5)                                      4615 (70.1)                  856 (55.4)                          \<0.0001
  Rhythm control                           3202 (31.7)                 566 (28.8)                                       1953 (29.7)                  683 (44.2)                          
  Prior cardioversion                      3037 (30.1)                 503 (25.6)                                       1887 (28.7)                  647 (41.9)                          \<0.0001
  1                                        1790 (58.9)                 313 (62.2)                                       1138 (60.3)                  339 (52.4)                          \<0.0001
  2                                        726 (23.9)                  118 (23.5)                                       448 (23.7)                   160 (24.7)                          
  ≥3                                       513 (16.9)                  72 (14.3)                                        294 (15.6)                   147 (22.7)                          
  Prior antiarrhythmic drug therapy        4573 (45.3)                 847 (43.0)                                       2824 (42.9)                  902 (58.4)                          \<0.0001
  1                                        2939 (64.3)                 568 (67.1)                                       1788 (63.3)                  583 (64.6)                          \<0.0001
  2                                        923 (20.2)                  159 (18.8)                                       549 (19.4)                   215 (23.8)                          
  ≥3                                       368 (8.1)                   71 (8.4)                                         203 (7.2)                    94 (10.4)                           
  Prior warfarin therapy                   8256 (81.8)                 1532 (77.8)                                      5403 (82.1)                  1321 (85.6)                         \<0.0001
  Catheter ablation of AF                  552 (5.5)                   100 (5.1)                                        320 (4.9)                    132 (8.6)                           \<0.0001
  Surgical/hybrid maze                     194 (1.9)                   32 (1.6)                                         104 (1.6)                    58 (3.8)                            \<0.0001
  AV node ablation                         220 (2.2)                   34 (1.7)                                         142 (2.2)                    44 (2.9)                            0.0778
  Rate control agents                                                                                                                                                                    
  Beta‐blocker                             6449 (63.9)                 1161 (59.0)                                      4270 (64.9)                  1018 (65.9)                         \<0.0001
  Dihydropyridine CCB                      1391 (13.8)                 315 (16.0)                                       884 (13.4)                   192 (12.4)                          0.0034
  Digoxin                                  2361 (23.4)                 445 (22.6)                                       1609 (24.4)                  307 (19.9)                          0.0005
  Antiarrhythmic drug therapy              2895 (28.7)                 480 (24.4)                                       1785 (27.1)                  630 (40.8)                          \<0.0001
  Amiodarone                               1002 (9.9)                  167 (8.5)                                        625 (9.5)                    210 (13.6)                          \<0.0001
  Dronedarone                              466 (4.6)                   68 (3.5)                                         320 (5.0)                    78 (5.1)                            0.0231
  Dofetilide                               190 (1.9)                   21 (1.1)                                         93 (1.4)                     76 (4.9)                            \<0.0001
  Flecainide                               290 (2.9)                   55 (2.8)                                         145 (2.2)                    90 (5.8)                            \<0.0001
  Propafenone                              236 (2.3)                   47 (2.4)                                         154 (2.3)                    35 (2.3)                            0.9714
  Sotalol                                  618 (6.1)                   90 (4.6)                                         398 (6.0)                    130 (8.4)                           \<0.0001
  Other[\*](#tf2-1){ref-type="table-fn"}   131 (1.3)                   36 (1.8)                                         77 (1.2)                     18 (1.2)                            0.0665
  Antithrombotic therapy (any use)         9579 (94.9)                 1833 (93.1)                                      6254 (95.0)                  1492 (96.6)                         \<0.0001
  Aspirin                                  4452 (44.1)                 745 (37.8)                                       2946 (44.7)                  761 (49.3)                          \<0.0001
  Clopidogrel                              712 (7.1)                   105 (5.3)                                        494 (7.5)                    113 (7.3)                           0.0040
  Prasugrel                                14 (0.1)                    3 (0.2)                                          9 (0.1)                      2 (0.1)                             0.9810
  Dabigatran                               496 (4.9)                   71 (3.6)                                         352 (5.4)                    73 (4.7)                            0.0070
  Warfarin                                 7198 (71.3)                 1381 (70.1)                                      4705 (71.5)                  1112 (72.0)                         0.4116
  Combination antithrombotic therapy                                                                                                                                                     
  Aspirin and warfarin                     2556 (25.3)                 373 (18.9)                                       1732 (26.3)                  451 (29.2)                          \<0.0001
  Aspirin and dabigatran                   155 (1.5)                   18 (0.9)                                         108 (1.6)                    29 (1.9)                            0.0353
  Aspirin, clopidogrel, and warfarin       165 (1.6)                   20 (1.0)                                         122 (1.9)                    23 (1.5)                            0.0330
  Clopidogrel and warfarin                 334 (3.3)                   44 (2.2)                                         230 (3.5)                    60 (3.9)                            0.0092
  Clopidogrel and dabigatran               13 (0.1)                    3 (0.2)                                          9 (0.1)                      1 (0.06)                            0.7371
  Aspirin, clopidogrel, and dabigatran     3 (0.03)                    1 (0.05)                                         1 (0.02)                     1 (0.06)                            0.4962
  Contraindications to anticoagulation     1407 (13.9)                 295 (15.0)                                       915 (13.9)                   197 (12.8)                          0.1667
  Management in anticoagulation clinic     3112 (43.2)                 459 (33.2)                                       2009 (42.7)                  644 (57.9)                          \<0.0001

AF indicates atrial fibrillation; AV, arterioventricular; CCB, calcium channel blocker.

Other includes disopyramide, ranolazine, quinidine, and other antiarrhythmic medications.

[Table 2](#tbl02){ref-type="table"} also displays the pharmacologic therapies for AF according to provider type. Overall, class III antiarrhythmic drugs (amiodarone, dronedarone, dofetilide, and sotalol) were the most prevalently used agents for all providers. Electrophysiology providers were more likely to use antiarrhythmic drugs, as well as antithrombotic agents (overall *P*\<0.01). Patients cared for by EP providers were more likely to have warfarin management from an anticoagulation clinic (58% versus 43% for cardiology and versus 33% for internal medicine/primary care), although the number of patients with contraindications to anticoagulation was similar across the provider groups (*P*=0.17).

Relationship Between Provider Specialty and Treatment Strategies: Adjusted Results
----------------------------------------------------------------------------------

[Table 3](#tbl03){ref-type="table"} shows the results for the adjusted association of provider specialty and the various treatment strategies. After adjusting for case mix, patients seen by an EP provider were more likely to be on rhythm control when compared with patients seen by a cardiology provider (adjusted OR, 1.66; 95% CI, 1.05 to 2.61; *P*=0.0301). Also, patients seen by an EP provider were more likely to have prior cardioversions than patients seen by a cardiology provider (adjusted OR, 1.39; 95% CI, 1.03 to 1.87; *P*=0.0292).

###### 

Adjusted Relationship Between Specialty of Care Provider and Treatment Strategies

  Care Process                                            Provider Specialty   Adjusted OR   Lower (95% CI for OR)   Upper (95% CI for OR)   *P* Value   Global *P* Value
  ------------------------------------------------------- -------------------- ------------- ----------------------- ----------------------- ----------- ------------------
  Rhythm control                                          EP (vs cardiology)   1.66          1.05                    2.61                    0.0301      0.0470
  FP/IM (vs cardiology)                                   0.91                 0.65          1.26                    0.5512                  ---         
  Prior cardioversion                                     EP (vs cardiology)   1.39          1.03                    1.87                    0.0292      0.0231
  FP/IM (vs cardiology)                                   0.88                 0.70          1.10                    0.2699                  ---         
  Oral anticoagulant (warfarin or dabigatran)             EP (vs cardiology)   1.25          0.71                    2.19                    0.4350      0.1500
  FP/IM (vs cardiology)                                   0.73                 0.49          1.09                    0.1233                  ---         
  Dabigatran vs warfarin                                  EP (vs cardiology)   1.11          0.49                    2.50                    0.8023      0.2395
  FP/IM (vs cardiology)                                   0.61                 0.32          1.13                    0.1179                  ---         
  Antiplatelet[\*](#tf3-1){ref-type="table-fn"}           EP (vs cardiology)   1.34          0.93                    1.92                    0.1132      \<0.0001
  FP/IM (vs cardiology)                                   0.60                 0.47          0.79                    0.0002                  ---         
  Anticoagulant clinic[\*](#tf3-2){ref-type="table-fn"}   EP (vs cardiology)   3.51          0.90                    13.67                   0.0705      0.0577
  FP/IM (vs cardiology)                                   0.60                 0.23          1.60                    0.3097                  ---         

OR indicates odds ratio; CI, confidence interval; EP, electrophysiology; FP, family practice; IM, internal medicine.

Aspirin, clopidogrel, prasugrel.

Analyses only among those on warfarin (n=7176).

Discussion
==========

This study examined differences in patient characteristics, type of AF, and treatment strategies among a large sample of outpatients who received care among a diverse group of provider specialties. Our analysis yielded 3 major findings. First, EP providers tended to care for those AF patients who were younger, healthier, white, at lower risk, and more likely to have paroxysmal or persistent AF. Second, EP providers were more likely to initiate rhythm control strategies, including antiarrhythmic therapy and/or ablation therapy, than those treated by cardiologists or internal medicine/primary care physicians. Finally, warfarin treatment was consistently high across providers, although internal medicine providers tended to use fewer antiplatelet agents and novel anticoagulant therapy than did the EP and cardiology providers.

Two previous studies examined AF care patterns among cardiology providers as part of the AF: Focus on Effective Clinical Treatment Strategies (AFFECTS) Registry.^[@b22]--[@b23]^ Patients enrolled in the AFFECTS Registry were treated with rhythm control in two thirds of the cases, whereas only one third of patients were treated with rhythm control in the ORBIT‐AF Registry. Furthermore, use of anticoagulants was slightly higher in the ORBIT‐AF Registry at baseline (76% versus 64%), although the 64% at baseline in the AFFECTS Registry increased to 73% at the end of the study period. We found similar rates of warfarin utilization among the 3 provider groups but different rates of overall anticoagulation use, with cardiology and EP providers prescribing warfarin or dabigatran more often than the internal medicine providers. These differences did not persist after multivariable adjustment, although the results suggested a trend. We also assessed provider‐level treatment guideline adherence for anticoagulation therapy singly according to CHA~2~DS~2~‐VASc score. Patients with a contraindication for oral anticoagulation were excluded, and the results showed that EP providers were more prone to employing anticoagulation treatment compared with cardiology providers and internal medicine/general practitioner providers for CHA~2~DS~2~‐VASc scores ≥2. For CHA~2~DS~2~‐VASc scores of 0 and 1, EP providers again tended to prescribe anticoagulants more often, but this did not reach statistical significance. Hence, EP providers are seemingly more aggressive in terms of stroke prophylaxis, and our results suggest that they adhere better to treatment guidelines compared with cardiology and internal medicine/general practitioner providers. Similarly, EP providers in the ORBIT‐AF Registry were more likely to select a rhythm control strategy than were the cardiology providers. This association persisted after accounting for type of AF and other patient characteristics. Overall, EP providers elected to prescribe stroke prevention prophylaxis and attempted to maintain sinus rhythm more frequently than other providers, yet the relative differences were moderate.

Provider specialty‐specific data for AF quality of care are sparse. In prior studies of heart failure management, patients treated by cardiologists tended to have higher resource utilization and better short‐term outcomes compared with other provider types.^[@b9]--[@b14]^ Atrial fibrillation is a chronic condition with substantial morbidity and has similarities as well as clinical overlap with both heart failure and the chronic phase of MI/stable angina, so it is not surprising that we observed similar management trends in our study. In general, patients cared for by EP providers received more rhythm control than rate control. We also observed that newer drugs, such as dabigatran, were used more often by EP and cardiology providers. In addition, we observed an interesting difference in patient race: white patients generally received more specialty care than patients of other races. Finally, patients in the EP group had more private health insurance and were less likely to have no health insurance than those in the other groups. This could easily influence the reference patterns and patient profiles in the groups. Importantly, we accounted for this in our models, and our findings in [Table 3](#tbl03){ref-type="table"} were independent of this observed difference.

Modern systems of health care are moving more toward multispecialty care and "disease‐state" centers. Accountable care organizations incorporate multiple specialties and providers into the parallel treatment of patients. In clinical practice, AF patients often require multiple specialty care providers. Although the differences between providers are relatively small, future studies should examine if these differences in therapeutic management are associated with different/improved outcomes.

This was an observational study and had several limitations. First, we used data from a voluntary clinical registry, so extrapolation to other care settings and providers should be done cautiously. Second, the provider specialty reported was the specialty of the clinic administrator and not of the individual clinician treating the patient. Third, we selected the types of practices participating in ORBIT‐AF; therefore, these results may not be fully representative of the overall distribution of provider specialties caring for AF in community practice. Finally, we do not have any information regarding prior patient physician contact and possible treatments for AF. In turn, information regarding the specific reason for AF care referral was not obtainable.

In conclusion, we found that in this large registry of outpatient AF patients, the delivering care provider\'s specialty was associated with differences in patient demographics, as well as in the care provided. Electrophysiologists were more likely to employ stroke prevention and rhythm control treatment strategies for their patients, whereas the patients of internal medicine/family practice providers received fewer antithrombotic agents. Patients cared for by internal medicine/family medicine providers were generally older. In light of our study\'s findings, appropriately risk‐adjusted outcomes data for comparison of various providers should be developed. These data should include net benefit estimations including thrombosis, as well as bleeding risks.
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